Trial Profile
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-MUC1 CAR-T cell therapy (Primary) ; Cyclophosphamide; Fludarabine
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 28 Aug 2018 New trial record